D
80.04
4.22 (5.57%)
| Previous Close | 75.82 |
| Open | 75.47 |
| Volume | 11,450,882 |
| Avg. Volume (3M) | 4,196,973 |
| Market Cap | 31,263,223,808 |
| Price / Earnings (TTM) | 48.51 |
| Price / Earnings (Forward) | 38.02 |
| Price / Sales | 8.19 |
| Price / Book | 15.39 |
| 52 Weeks Range | |
| Earnings Date | 6 Feb 2025 - 10 Feb 2025 |
| Profit Margin | 17.22% |
| Operating Margin (TTM) | 15.29% |
| Diluted EPS (TTM) | 1.65 |
| Quarterly Revenue Growth (YOY) | 2.00% |
| Quarterly Earnings Growth (YOY) | 11.50% |
| Total Debt/Equity (MRQ) | 130.94% |
| Current Ratio (MRQ) | 2.46 |
| Operating Cash Flow (TTM) | 821.70 M |
| Levered Free Cash Flow (TTM) | 353.22 M |
| Return on Assets (TTM) | 6.06% |
| Return on Equity (TTM) | 32.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | DexCom, Inc. | Bearish | Bearish |
AIStockmoo Score
1.3
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 97.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (RBC Capital, 43.68%) | Buy |
| Median | 94.00 (17.44%) | |
| Low | 85.00 (JP Morgan, 6.20%) | Hold |
| Average | 95.67 (19.53%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 75.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Dec 2024 | 91.00 (13.69%) | Buy | 80.47 |
| Wells Fargo | 11 Dec 2024 | 94.00 (17.44%) | Buy | 80.47 |
| 25 Oct 2024 | 90.00 (12.44%) | Buy | 73.44 | |
| Canaccord Genuity | 09 Dec 2024 | 99.00 (23.69%) | Buy | 78.41 |
| Bernstein | 25 Oct 2024 | 86.00 (7.45%) | Buy | 73.44 |
| JP Morgan | 25 Oct 2024 | 85.00 (6.20%) | Hold | 73.44 |
| Leerink Partners | 25 Oct 2024 | 87.00 (8.70%) | Buy | 73.44 |
| Oppenheimer | 25 Oct 2024 | 105.00 (31.18%) | Buy | 73.44 |
| RBC Capital | 25 Oct 2024 | 115.00 (43.68%) | Buy | 73.44 |
| 08 Oct 2024 | 120.00 (49.93%) | Buy | 69.43 | |
| Raymond James | 25 Oct 2024 | 99.00 (23.69%) | Buy | 73.44 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Dec 2024 | Announcement | Dexcom Launches the First Generative AI Platform in Glucose Biosensing |
| 17 Dec 2024 | Announcement | Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM |
| 19 Nov 2024 | Announcement | Dexcom and ŌURA Announce Strategic Partnership |
| 14 Nov 2024 | Announcement | Dexcom Helps People With Diabetes Take the First Step to Discover What They’re Made Of on World Diabetes Day |
| 29 Oct 2024 | Announcement | Glucoguard, a Division of ADHC, Completes AI Based Mobile Application and Design Outline (MADO) for Dexcom API Integration |
| 24 Oct 2024 | Announcement | Dexcom Reports Third Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |